As EGF signaling positively regulates CHD6 expression, we rationalized that anti-EGFR monoclonal antibody Cetuximab can be exploited for treatment of CHD6-overexpressing CRC (Fig. 8b). Here, EGFR is linked to colorectal carcinoma.